OVERVIEW

New Frontiers and Therapeutic Advances for Metastatic Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors is organized by CMEducation Resources, LLC.

Course Overview :
In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of metastatic pancreatic cancer.

Conference Objectives are :
Upon completion of this activity, participants will be able to:
• Detail the epidemiology, burden, and clinical challenges associated with detecting, diagnosing and classifying metastatic pancreatic adenocarcinoma and pancreatic neuroendocrine tumor (panNET)
• Outline the recently issued, Spring 2017 NCCN clinical practice guidelines for metastatic pancreatic adenocarcinoma and pancreatic neuroendocrine tumor (panNET); and, therefore, become more clinically proficient at applying these evidence-?based guidelines to the from lines of GI oncology practice
• Determine which patients with metastatic pancreatic cancer are appropriate for the use of surgical interventions (resection), medical therapy, and/or systemic chemotherapy, based on presentation, symptoms, tumor types and stage, clinical profiles, extent of disease, biomarkers, and other factors
• Deploy evidence-?based, guideline-?adherent therapies treatments for patients with metastatic pancreatic adenocarcinoma, including such regimens based on gemcitabine, FOLFIRINOX, nanoliposomal irinotecan, and other agents; and how to sequence them in the context of multimodal -? surgical and chemotherapeutic -? approaches to comprehensive management of pancreatic carcinoma
• Deploy evidence-?based, guideline-?adherent therapies treatments for patients with panNET, including the use of somatostatin analogs (SSAs) for symptom relief and antiproliferative properties, radiolabeled SSAs, cytotoxic drugs, angiogenesis inhibitors, and other therapies

Additional details will be posted as soon as information is available.